114TH CONGRESS 
2D SESSION 
H. R. 4586 
AN ACT 
To amend the Public Health Service Act to authorize grants 
to States for developing standing orders and educating 
health care professionals regarding the dispensing of 
opioid overdose reversal medication without person-spe-
cific prescriptions, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE. 
This Act may be cited as ‘‘Lali’s Law’’. 
SEC. 2. OPIOID OVERDOSE REVERSAL MEDICATION ACCESS 
AND EDUCATION GRANT PROGRAMS. 
(a) TECHNICAL CLARIFICATION.—Effective as if in-
cluded in the enactment of the Children’s Health Act of 
2000 (Public Law 106–310), section 3405(a) of such Act 
(114 Stat. 1221) is amended by striking ‘‘Part E of title 
III’’ and inserting ‘‘Part E of title III of the Public Health 
Service Act’’. 
(b) AMENDMENT.—Title III of the Public Health 
Service Act is amended by inserting after part D of such 
title (42 U.S.C. 254b et seq.) the following new part E: 
‘‘PART E—OPIOID USE DISORDER 
‘‘SEC. 341. OPIOID OVERDOSE REVERSAL MEDICATION AC-
CESS AND EDUCATION GRANT PROGRAMS. 
‘‘(a) GRANTS TO STATES.—The Secretary may make 
grants to States for— 
‘‘(1) developing standing orders for pharmacies 
regarding opioid overdose reversal medication; 
‘‘(2) encouraging pharmacies to dispense opioid 
overdose reversal medication pursuant to a standing 
order; 
‘‘(3) implementing best practices for persons 
authorized to prescribe medication regarding—
‘‘(A) prescribing opioids for the treatment 
of chronic pain; 
‘‘(B) co-prescribing opioid overdose rever-
sal medication with opioids; and 
‘‘(C) discussing the purpose and adminis-
tration of opioid overdose reversal medication 
with patients; 
‘‘(4) developing or adapting training materials 
and methods for persons authorized to prescribe or 
dispense medication to use in educating the public 
regarding— 
‘‘(A) when and how to administer opioid 
overdose reversal medication; and 
‘‘(B) steps to be taken after administering 
opioid overdose reversal medication; and 
‘‘(5) educating the public regarding— 
‘‘(A) the public health benefits of opioid 
overdose reversal medication; and 
‘‘(B) the availability of opioid overdose re-
versal medication without a person-specific pre-
scription. 
‘‘(b) CERTAIN REQUIREMENT.—A grant may be 
made under this section only if the State involved has au-
thorized standing orders regarding opioid overdose rever-
sal medication.
‘‘(c) PREFERENCE IN MAKING GRANTS.—In making 
grants under this section, the Secretary shall give pref-
erence to States that— 
‘‘(1) have not issued standing orders regarding 
opioid overdose reversal medication; 
‘‘(2) authorize standing orders that permit com-
munity-based organizations, substance abuse pro-
grams, or other nonprofit entities to acquire, dis-
pense, or administer opioid overdose reversal medica-
tion; 
‘‘(3) authorize standing orders that permit po-
lice, fire, or emergency medical services agencies to 
acquire and administer opioid overdose reversal 
medication; 
‘‘(4) have a higher per capita rate of opioid 
overdoses than other applicant States; or 
‘‘(5) meet any other criteria deemed appro-
priate by the Secretary. 
‘‘(d) GRANT TERMS.— 
‘‘(1) NUMBER.—A State may not receive more 
than one grant under this section. 
‘‘(2) PERIOD.—A grant under this section shall 
be for a period of 3 years. 
‘‘(3) AMOUNT.—A grant under this section may 
not exceed $500,000.
‘‘(4) LIMITATION.—A State may use not more 
than 20 percent of a grant under this section for 
educating the public pursuant to subsection (a)(5). 
‘‘(e) APPLICATIONS.—To be eligible to receive a grant 
under this section, a State shall submit an application to 
the Secretary in such form and manner and containing 
such information as the Secretary may require, including 
detailed proposed expenditures of grant funds. 
‘‘(f) REPORTING.—Not later than 3 months after the 
Secretary disburses the first grant payment to any State 
under this section and every 6 months thereafter for 3 
years, such State shall submit a report to the Secretary 
that includes the following: 
‘‘(1) The name and ZIP Code of each pharmacy 
in the State that dispenses opioid overdose reversal 
medication under a standing order. 
‘‘(2) The total number of opioid overdose rever-
sal medication doses dispensed by each such phar-
macy, specifying how many were dispensed with or 
without a person-specific prescription. 
‘‘(3) The number of pharmacists in the State 
who have participated in training pursuant to sub-
section (a)(4). 
‘‘(g) DEFINITIONS.—In this section:
‘‘(1) OPIOID
OVERDOSE
REVERSAL
MEDICA-
TION.—The term ‘opioid overdose reversal medica-
tion’ means any drug, including naloxone, that— 
‘‘(A) blocks opioids from attaching to, but 
does not itself activate, opioid receptors; or 
‘‘(B) inhibits the effects of opioids on 
opioid receptors. 
‘‘(2) STANDING
ORDER.—The term ‘standing 
order’ means a document prepared by a person au-
thorized to prescribe medication that permits an-
other person to acquire, dispense, or administer 
medication without a person-specific prescription. 
‘‘(h) AUTHORIZATION OF APPROPRIATIONS.— 
‘‘(1) IN GENERAL.—To carry out this section, 
there is authorized to be appropriated $5,000,000 
for the period of fiscal years 2017 through 2019. 
‘‘(2) ADMINISTRATIVE COSTS.—Not more than 
3 percent of the amounts made available to carry 
out this section may be used by the Secretary for 
administrative expenses of carrying out this sec-
tion.’’. 
SEC. 3. CUT-GO COMPLIANCE. 
Subsection (f) of section 319D of the Public Health 
Service Act (42 U.S.C. 247d–4) is amended by inserting 
before the period at the end the following: ‘‘(except such
dollar amount shall be reduced by $5,000,000 for fiscal 
year 2017)’’. 
Passed the House of Representatives May 12, 2016. 
Attest: 
Clerk.
114TH CONGRESS 
2D SESSION 
H. R. 4586 
AN ACT 
To amend the Public Health Service Act to author-
ize grants to States for developing standing or-
ders and educating health care professionals re-
garding the dispensing of opioid overdose reversal 
medication without person-specific prescriptions, 
and for other purposes.